Article
Resolvin E1 derived from eicosapentaenoic acid prevents hyperinsulinemia and hyperglycemia in a host genetic manner
2019-11-20
Abstract excerpt
<h4>ABSTRACT</h4> <h4>Objective</h4> Eicosapentaenoic acid (EPA) has recently garnered strong attention given the success of the REDUCE-IT trial, which overturned previous conclusions on EPA and led to its FDA approval for lowering cardiovascular disease risk. Therefore, there is a need to study EPA for cardiometabolic risk factors. Here we focused on EPA’s preventative role on hyperglycemia and hyperinsulinemia...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 3a2f4124-5894-5355-8881-ed7730fdb04d
- DOI
- 10.1101/848093
